0000950170-24-038455.txt : 20240329 0000950170-24-038455.hdr.sgml : 20240329 20240329103609 ACCESSION NUMBER: 0000950170-24-038455 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240321 FILED AS OF DATE: 20240329 DATE AS OF CHANGE: 20240329 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Erickson Anne CENTRAL INDEX KEY: 0002016865 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 24802485 MAIL ADDRESS: STREET 1: 1717 LANGHORNE NEWTOWN RD. SUITE 300 CITY: LANGHORNE STATE: PA ZIP: 19047 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Savara Inc CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6836 BEE CAVE ROAD STREET 2: BUILDING 3, SUITE 201 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 51285113796 MAIL ADDRESS: STREET 1: 6836 BEE CAVE ROAD STREET 2: BUILDING 3, SUITE 201 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER COMPANY: FORMER CONFORMED NAME: Mast Therapeutics, Inc. DATE OF NAME CHANGE: 20130312 FORMER COMPANY: FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030613 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 3 1 ownership.xml 3 X0206 3 2024-03-21 0 0001160308 Savara Inc SVRA 0002016865 Erickson Anne 1717 LANGHORNE NEWTOWN ROAD SUITE 300 LANGHORNE PA 19047 false true false false Chief Business Officer Common Stock 354078 D Stock Option (Right to Buy) 10.01 2028-10-18 Common Stock 20000 D Stock Option (Right to Buy) 11.00 2029-05-30 Common Stock 2000 D Stock Option (Right to Buy) 1.57 2029-12-17 Common Stock 25000 D Stock Option (Right to Buy) 1.13 2030-10-21 Common Stock 75000 D Stock Option (Right to Buy) 1.23 2030-12-16 Common Stock 50000 D Stock Option (Right to Buy) 1.11 2031-12-14 Common Stock 50000 D Stock Option (Right to Buy) 1.51 2032-12-13 Common Stock 150000 D Stock Option (Right to Buy) 4.45 2033-12-14 Common Stock 40000 D 4,687 represents restricted stock units ("RSUs") that vest in substantially equal installments on April 21, 2024, July 21, 2024, and October 21, 2024; 75,000 represents RSUs that vest in full on December 13, 2024; and 160,000 represents RSUs that vest in full on December 14, 2025, in each case subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of October 18, 2018, subject to the reporting person's continued service with the Issuer. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of May 30, 2019, subject to the reporting person's continued service with the Issuer. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 17, 2019, subject to the reporting person's continued service with the Issuer. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of October 21, 2020, subject to the reporting person's continued service with the Issuer. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 16, 2020, subject to the reporting person's continued service with the Issuer. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 14, 2021, subject to the reporting person's continued service with the Issuer. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 13, 2022, subject to the reporting person's continued service with the Issuer. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 14, 2023, subject to the reporting person's continued service with the Issuer. /s/ Anne Erickson 2024-03-28 EX-24 2 svra-ex24.htm EX-24 EX-24

 

 

 

 

LIMITED POWER OF ATTORNEY FOR SECTION 16(a) REPORTING

 

KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints each of David L. Lowrance and Kathleen R. McCabe, and each of their successors in the offices of Chief Financial & Administrative Officer or Senior Vice President and General Counsel of Savara Inc. (the “Company”), as the undersigned's true and lawful attorney-in-fact (the “Attorney-in Fact”), with full power of substitution and resubstitution, each with the power to act alone for the undersigned and in the undersigned's name, place and stead, in any and all capacities to:

 

1.
prepare, execute, deliver and file with the United States Securities and Exchange Commission, any national securities exchange and the Company any and all reports (including any amendment thereto) of the undersigned required or considered advisable under Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder, with respect to the equity securities of the Company, including Form 3 (Initial Statement of Beneficial Ownership of Securities), Form 4 (Statement of Changes in Beneficial Ownership) and Form 5 (Annual Statement of Changes in Beneficial Ownership) and any successor forms thereto; and

 

2.
seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's equity securities from any third party, including the Company, brokers, dealers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such third party to release any such information to the Attorney-in-Fact.

 

The undersigned acknowledges that:

 

1.
this Limited Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act at his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information;

 

2.
any documents prepared and/or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary or desirable;

 

3.
neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility to comply with the requirements of Section 16 of the Exchange Act, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act; and

 

4.
this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 16 of the Exchange Act, including, without, limitation, the reporting requirements under Section 16(a) of the Exchange Act.

 

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or convenient to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by authority of this Limited Power of Attorney. This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with

respect to the undersigned's holdings of and transactions in equity securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact. This Limited Power of Attorney shall be governed and construed in accordance the laws of the State of Texas without

regard to the laws that might otherwise govern under applicable principles of conflicts of laws thereof.

 

(Signature page follows.)

 

 

IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney for Section 16(a) Reporting to be executed as of March 28, 2024.

 

 

 

Signature: ____/s/ Anne Erickson____________

 

Print Name: __Anne Erickson________________